ライフサイエンスコーパス: heart disease

1 farction, ischemic stroke, or fatal coronary heart disease).

2 ion in patients after surgery for congenital heart disease.

3 ute myocardial infarction or stable ischemic heart disease.

4 ac stem/progenitor cell therapy for ischemic heart disease.

5 rrhythmias in patients with various types of heart disease.

6 r disease, and those with prevalent coronary heart disease.

7 M2.5 with circulatory mortality and ischemic heart disease.

8 onfirmed in patients suffering from ischemic heart disease.

9 pendent and causal risk factors for coronary heart disease.

10 stacles in the prevention of and therapy for heart disease.

11 a primary cause of death among patients with heart disease.

12 ignant VTs occur in patients with structural heart disease.

13 died during follow-up, and 22 152 died from heart disease.

14 a promising target for novel therapeutics in heart disease.

15 nditions including functional and structural heart disease.

16 llary pulmonary hypertension because of left heart disease.

17 x, time of symptom onset, and known ischemic heart disease.

18 e each individually associated with coronary heart disease.

19 eutic strategy in contraception, cancer, and heart disease.

20 ecently reported increase in death rate from heart disease.

21 cial consideration of treating patients with heart disease.

22 cardiovascular disease, especially ischaemic heart disease.

23 ease, pulmonary hypertension, and congenital heart disease.

24 both were causally associated with coronary heart disease.

25 profiles, have reduced incidence of coronary heart disease.

26 gnostic and therapeutic targets for ischemic heart disease.

27 but if inappropriately sustained can worsen heart disease.

28 ng 10 195 patients with established coronary heart disease.

29 tion is an excellent treatment for end-stage heart disease.

30 h QTc prolongation in patients with ischemic heart disease.

31 e and function may help to prevent and treat heart disease.

32 ticularly on PHVD associated with congenital heart disease.

33 requently occur in the context of structural heart disease.

34 myocardial injury in subjects with ischemic heart disease.

35 air pollution in individuals with ischaemic heart disease.

36 e a potential therapeutic target in ischemic heart disease.

37 n 12% to 13% of patients with PH due to left heart disease.

38 ing complication in patients with congenital heart disease.

39 damaged myocardium in patients with ischemic heart disease.

40 ty of echocardiographic studies for valvular heart disease.

41 that excluded participants with diabetes or heart disease.

42 ortant diagnostic information about ischemic heart diseases.

43 aphy in the diagnosis of congenital cyanotic heart diseases.

44 ence interval (CI): 1.04, 1.22) for coronary heart disease, 1.20 (95% CI: 1.01, 1.42) for heart failu

45 0th and 10th percentile was 2.0 for ischemic heart disease (119.1 vs 235.7 deaths per 100000 persons)

46 ervention for pediatric and adult congenital heart disease (20,169 procedures in 76 hospitals).

47 (95% CI, -42.6 to -9.4); death from coronary heart disease, -21.7 (95% CI, -37.1 to -6.4); and hospit

48 g 506100 from heart disease (371266 coronary heart disease, 35019 hypertensive heart disease, and 998

49 occurred in US adults, including 506100 from heart disease (371266 coronary heart disease, 35019 hype

50 annual medical expenditures, especially for heart disease ($4,595; 95% CI, $3,262 to $5,927) and str

51 that 7.2 (95% CI: -1.2, 15) would be due to heart disease, 4.0 (95% CI: -0.8, 8.2) due to respirator

52 ths per 100000 persons) to 4.2 (hypertensive heart disease: 4.3 vs 17.9 deaths per 100000 persons).

53 onary vascular disease (1.2%-7.1%), valvular heart disease (5.0%-9.8%), and renal failure (7.1%-19.6%

54 The number of patients with adult congenital heart disease (ACHD) is rapidly increasing.

55 t the CXCR4 locus with the risk for coronary heart disease, along with CXCR4 transcript expression in

56 Studies on chronic inflammatory diseases, heart diseases, Alzheimer's disease, and multiple sclero

57 tios for cardiovascular disease and coronary heart disease among participants who consumed 1 serving

58 istics ranged from 0.66 to 0.67 for ischemic heart disease and 0.68 to 0.72 for stroke.

59 her enrolled 4726 participants with coronary heart disease and 3529 controls.

60 .2DS, a total of 62% (n=906) have congenital heart disease and 36% (n=326) of these have tetralogy of

61 were 2734 deaths due to critical congenital heart disease and 3967 deaths due to other/unspecified c

62 CM) are increasingly being used for modeling heart disease and are under development for regeneration

63 rs are contraindicated in patients with both heart disease and asthma.

64 times and 5.9 times more at risk of ischemic heart disease and cardiomyopathy/heart failure death, re

65 d as an independent risk factor for coronary heart disease and cardiovascular mortality.

66 tality, defined as death because of coronary heart disease and cerebrovascular or other atherosclerot

67 declined, the devastating impact of chronic heart disease and comorbidities on quality of life and h

68 Among the birth defects, congenital heart disease and craniofacial malformations are major c

69 -/-) mice recapitulate features of diastolic heart disease and define previously unappreciated roles

70 anagement of VT in the setting of structural heart disease and discuss the evolving role of catheter

71 ated in causing excess deaths from ischaemic heart disease and exacerbations of COPD.

72 In a patient with congenital heart disease and heterotaxy, a disorder of left-right p

73 f hypertension, diabetes mellitus, ischaemic heart disease and hyperlipidemia.

74 Chinese patients with coronary heart disease and impaired glucose tolerance were random

75 PRETATION: In Chinese patients with coronary heart disease and impaired glucose tolerance, acarbose d

76 n screening policies for critical congenital heart disease and infant death rates.

77 reatment of congenital, as well as acquired, heart disease and likewise would enable development of p

78 ct of pravastatin versus placebo on coronary heart disease and major adverse cardiovascular events we

79 tic stenosis and the presence of concomitant heart disease and medical comorbidities, stress testing

80 -generation sequencing focused on congenital heart disease and neurodevelopmental disorders (NDDs).

81 ective review of 25 patients with congenital heart disease and post-operative chylothorax who present

82 festations of HF in children with congenital heart disease and presents the clinical, genetic, and mo

83 improving survival in patients with ischemic heart disease and reduced ejection fraction.

84 Furthermore, comorbidities such as valvular heart disease and renal failure as well as an early AF r

85 In patients with congenital heart disease and right bundle branch block, RV cardiac

86 HR: 0.33; 95% CI: 0.19 to 0.57) for coronary heart disease and stroke combined (p for trend <0.001).

87 arp decline in mortality rates from coronary heart disease and stroke has become unmistakable through

88 then the decline in mortality from coronary heart disease and stroke has been the success story of t

89 aimed to predict individual risk of ischemic heart disease and stroke in 5-year survivors of childhoo

90 at a significant recent downtick in coronary heart disease and stroke mortality rates had definitely

91 al differences exist between county ischemic heart disease and stroke mortality rates.

92 Results Ischemic heart disease and stroke occurred in 265 and 295 CCSS pa

93 Outcomes included cumulative CVD (coronary heart disease and stroke) deaths prevented or postponed

94 age 50 years for the development of ischemic heart disease and stroke.

95 rategy differs between those with structural heart disease and those without.

96 uggests daily low-dose aspirin (ASA) reduces heart diseases and colorectal cancers.

97 was 32 [13%] of 247 individuals for coronary heart disease), and respiratory conditions (eg, highest

98 ed from CVD, 4.9% had suffered from coronary heart disease, and 2.6% had experienced a stroke.

99 s, 44 (4.5%) had lung disease, 26 (2.6%) had heart disease, and 9 (0.9%) had HIV.

100 6 coronary heart disease, 35019 hypertensive heart disease, and 99815 other cardiovascular disease),

101 re on the risk of mortality from all causes, heart disease, and lung cancer using the parametric g-fo

102 e excess mortality from respiratory cancers, heart disease, and other causes resulting from occupatio

103 festyles and fewer risk factors for coronary heart disease, and particularly those with favorable lip

104 alcohol use, poor self-rated health, cancer, heart disease, and respiratory disease (ORs of two to th

105 tudy (1986 to 2012) who were free of cancer, heart disease, and stroke at baseline.

106 of nuts and cardiovascular disease, coronary heart disease, and stroke risk.

107 at least two from: type 2 diabetes, coronary heart disease, and stroke) in adults who are overweight

108 at least two from: type 2 diabetes, coronary heart disease, and stroke).

109 ardial infarction or death owing to coronary heart disease, and stroke, defined as the first nonfatal

110 ension, chronic kidney disease, HF, coronary heart disease, and stroke.

111 Lipid Disorders, Rhythm Disorders, Valvular Heart Disease, and Vascular Medicine (1-84).

112 dations for patients with prevalent coronary heart disease, and we offer recommendations, when data a

113 ng the diagnosis and management of carcinoid heart disease are lacking.

114 ence and morbidity of hypertension, coronary heart disease, arrhythmia, heart failure, and stroke.

115 prevalence of and mortality due to rheumatic heart disease as part of the 2015 Global Burden of Disea

116 density lipoprotein cholesterol and coronary heart disease at APOB were cis-methylation quantitative

117 luding assessment of structural and residual heart disease before and after surgery, quantification o

118 ement fibrosis and progression of structural heart disease before symptoms is fundamental to understa

119 dL, pravastatin reduced the risk of coronary heart disease by 27% (P=0.033) and major adverse cardiov

120 between miRNAs and their targetome in Chagas heart disease by integrating gene and microRNA expressio

121 ty and all-cause and leading cause-specific (heart disease, cancer, and stroke) mortality rates.

122 associations were observed for deaths due to heart disease, cancer, respiratory disease, stroke, diab

123 Next we evaluate known human congenital heart diseases: cardiomyopathy and heterotaxy.

124 , VT that occurs in patients with structural heart disease carries an elevated risk for sudden cardia

125 incident CVD events, including 916 coronary heart disease cases, were reported.

126 he relative risk of mortality from ischaemic heart disease, cerebrovascular disease, chronic obstruct

127 In addition to ischemic heart disease, certain nonischemic conditions may also h

128 Congenital heart disease (CHD) affects up to 1% of live births.

129 ry calcium (CAC) is associated with coronary heart disease (CHD) and cardiovascular disease (CVD); ho

130 The association of coronary heart disease (CHD) and human immunodeficiency virus (HI

131 ere the primary trial outcomes, and coronary heart disease (CHD) and overall CVD were additional desi

132 ar nodal reentrant tachycardia to congenital heart disease (CHD) and the outcome of catheter ablation

133 Patients with congenital heart disease (CHD) are assumed to be vulnerable to atri

134 Adults with congenital heart disease (CHD) are exposed to increasing amounts of

135 ospective studies supplemented with coronary heart disease (CHD) data from CARDIoGRAMplusC4D (Coronar

136 long-term risks of acute and fatal coronary heart disease (CHD) events after sepsis hospitalizations

137 tients may be at increased risk for coronary heart disease (CHD) events and mortality.

138 Congenital heart disease (CHD) is the leading cause of mortality fr

139 Blacks have higher coronary heart disease (CHD) mortality compared with whites.

140 e are now more adults living with congenital heart disease (CHD) than children.

141 Whether disclosing genetic risk for coronary heart disease (CHD) to individuals influences informatio

142 length (TL) to be a risk factor for coronary heart disease (CHD), and recently the association was su

143 ces of incident heart failure (HF), coronary heart disease (CHD), and stroke in participants with vs

144 isease (CVD) mortality and incident coronary heart disease (CHD), CVD, and cancer over a mean 8.9 (st

145 morbidity associated with complex congenital heart disease (CHD), while the underlying biological mec

146 model to predict outcomes in stable coronary heart disease (CHD).

147 tachyarrhythmias in patients with congenital heart disease (CHD).

148 demonstrate a reduction in risk for coronary heart disease (CHD).

149 ned by apoC-III are associated with coronary heart disease (CHD).

150 associated with type 2 diabetes and coronary heart disease (CHD).

151 ion to blood lipid levels and hence coronary heart disease (CHD).

152 ars; 39% women) with 62240 cases of coronary heart disease (CHD).

153 of 4 cardiovascular presentations (coronary heart disease [CHD], cerebrovascular disease, heart fail

154 with first-ever CVD outcomes (i.e., coronary heart disease [CHD], stroke, or the combination of both)

155 whereas 172 suffered from a chronic ischemic heart disease (CIHD), 126 of whom underwent challenges.

156 ortality rates for ischemic and hypertensive heart disease compared with other subgroups, whereas Mex

157 thmias due to IART increased with congenital heart disease complexity from 47.2% to 62.1% to 67.0% in

158 d the future risk of heart failure, coronary heart disease, composite cardiovascular disease, death b

159 yed echocardiographic characteristics of the heart disease condition, yet only aged HCM females displ

160 yocardial & Pericardial Diseases, Congenital Heart Disease, Coronary Disease & Interventions, and CVD

161 opulation derived from the Quebec Congenital Heart Disease Database.

162 Critical congenital heart disease death rates in states with mandatory scree

163 initial trial phase and the risk of coronary heart disease death, cardiovascular death, and all-cause

164 inly because of declines in HIV, cancer, and heart disease deaths, resulting in an estimated 112 000

165 table women but can cause a second cancer or heart disease decades later.

166 age-standardized mortality due to rheumatic heart disease decreased by 47.8% (95% uncertainty interv

167 Incident CVD, which combines coronary heart disease, defined as the first incident myocardial

168 come in the care of patients with congenital heart disease depends on a comprehensive multidisciplina

169 s with hypertrophic cardiomyopathy, ischemic heart disease, diabetes mellitus, and more.

170 nt and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapi

171 nt and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapy

172 tic effects on the indexing (first) coronary heart disease event.

173 ecause cancer patients often have coexisting heart diseases, expert advice from cardiologists will im

174 t decades, the landscape of adult congenital heart disease has changed dramatically, which has to be

175 Percutaneous therapies for congenital heart disease have evolved rapidly in the past 3 decades

176 confidence interval, 1.14-1.87) and coronary heart disease (hazard ratio, 1.56; 95% confidence interv

177 ensable tool in the evaluation of congenital heart disease, heart failure, cardiac masses, pericardia

178 d myocardium from patients with hypertensive heart disease (HHD) and heart failure with preserved eje

179 We examined hypertension, heart disease, high cholesterol, stroke, arthritis, asth

180 g patients with diabetes and stable ischemic heart disease, higher SYNTAX scores predict higher rates

181 n is an effective means of treating ischemic heart disease; however, current therapeutic revasculariz

182 e (HR = 1.09, 95% CI: 1.02, 1.16), pulmonary heart disease (HR = 1.08, 95% CI: 1.00, 1.16), and respi

183 er (HR = 1.08, 95% CI: 1.02, 1.14), ischemic heart disease (HR = 1.09, 95% CI: 1.02, 1.16), pulmonary

184 (HR, 0.57; 95% CI, 0.34-0.97) and congenital heart disease (HR, 0.78; 95% CI, 0.64-0.96).

185 32), but higher risks of death from coronary heart disease (HR: 1.45; 95% CI: 1.21 to 1.74), myocardi

186 aminotransferase (ALT) levels with ischaemic heart disease (IHD) and cardiovascular disease (CVD) ris

187 The pathogenic role of ischemic heart disease (IHD) in heart failure (HF) with reduced e

188 id arthritis (RA) is independent of ischemic heart disease (IHD).

189 oronary arteries from patients with ischemic heart disease implying a role in human arterial disease.

190 297,300 to 337,300) deaths due to rheumatic heart disease in 2015.

191 meters in individuals free of prior coronary heart disease in four different ethnicities.

192 th nearly a doubling in the risk of coronary heart disease in humans and with accelerated atheroscler

193 sing the largest subset of severe congenital heart disease in the cohort.

194 from 3313 patients with established coronary heart disease in the Ludwigshafen Risk and Cardiovascula

195 nfarction (MI) is the most prevalent form of heart disease in the United States.

196 ong ncRNAs and circular RNAs, across various heart diseases indicates that ncRNAs are critical contri

197 documents addressing ACS and stable ischemic heart disease individually.

198 ch for training and assessment of structural heart disease interventional skills.

199 p of patients, those who survived congenital heart disease into adulthood, emerged.

200 tive chylothorax in patients with congenital heart disease is a challenging problem with substantial

201 Carcinoid heart disease is a frequent occurrence in patients with

202 reduced ejection fraction caused by ischemic heart disease is associated with increased morbidity and

203 predict progression to death after coronary heart disease is established.

204 The pathophysiology of carcinoid heart disease is poorly understood; however, chronic exp

205 Congenital heart disease is the most common birth defect, and becau

206 pulmonary venous pressure secondary to left heart disease is the most common cause of pulmonary hype

207 Congenital heart disease is the most frequently occurring congenita

208 Ischemic heart disease is the number one cause of death of women

209 Ischaemic heart disease limits oxygen and metabolic substrate avai

210 categories (eg, diabetes mellitus, ischemic heart disease, liver disease).

211 existing drugs approved for the treatment of heart disease may provide a novel therapeutic approach f

212 s lost for neoplasms (men: 0.7; women: 0.4), heart diseases (men: 1.2; women: 0.3), and respiratory d

213 l may constitute a potential cell source for heart disease modeling, drug screening, and cell-based t

214 icant positive association between PM2.5 and heart disease mortality (hazard ratio, 1.16; 95% confide

215 a 0.54% (95% CI: -0.17%, 1.25%) increase in heart disease mortality, a 2.71% (95% CI: 2.21%, 3.22%)

216 e intervals (CIs) for all-cause and coronary heart disease mortality, myocardial infarction, repeat r

217 nfatal myocardial infarction, other coronary heart disease mortality, or stroke; (3) ASCV mortality,

218 Twenty sepsis patients, 11 ischemic heart disease, nine dilated cardiomyopathy, and 11 nonfa

219 ingestion of inorganic arsenic and ischemic heart disease, nonmalignant respiratory disease, and lun

220 Ischemic heart disease (odds ratio [OR], 7.21; P < 0.001) and gre

221 0 to 35 years of age undergoing a congenital heart disease operation in the Society of Thoracic Surge

222 igher in patients with a history of ischemic heart disease or atrial fibrillation.

223 Structural heart disease or inadvertent pacing in scar was not asso

224 months of age) coded for critical congenital heart disease or other/unspecified congenital cardiac ca

225 ith angiographically proven stable ischaemic heart disease or stage 2 Global initiative for Obstructi

226 s associated with a reduced risk of coronary heart disease (OR 0.98; 95% CI 0.96, 0.99; P = 5.9 x 10(

227 Heart disease (OR 1.37, 95% CI 1.12-1.67), hypertension

228 abundance in septic cardiomyopathy, ischemic heart disease, or dilated cardiomyopathy, in comparison

229 nfatal myocardial infarction, fatal coronary heart disease, or heart failure.

230 pants with a diagnosis of diabetes, coronary heart disease, or stroke at or before study baseline.

231 s a history of atrial fibrillation, ischemic heart diseases, or congestive heart failure.

232 ditions (hypertension: OR [odds ratio] 1.43; heart disease: OR 1.68; high cholesterol: OR 1.26; strok

233 prevalence of and mortality due to rheumatic heart disease over a 25-year period.

234 irculatory disease (p = 0.014) and ischaemic heart disease (p = 0.003), possibly due to competing cau

235 008 and Ptriglycerides=0.00003) and coronary heart disease (P=0.0007).

236 In the care of patients with congenital heart disease, percutaneous interventional treatments ha

237 sociated with many human diseases, including heart disease, progeria, and cancer.

238 rt failure, ischemic heart disease, valvular heart disease, pulmonary hypertension, and congenital he

239 The diagnosis of PH due to left heart disease relies on a clinical probability assessmen

240 Rheumatic heart disease remains an important preventable cause of

241 tality in patients with established coronary heart disease remains less clear.

242 Heart disease remains the leading cause of death globall

243 rs, admission >/=14 days of life, congenital heart disease requiring surgical repair at <7 days of li

244 Ischemic heart disease resulting from myocardial infarction (MI)

245 Rheumatic heart disease (RHD) is a leading cause of premature deat

246 acific experience a high burden of rheumatic heart disease (RHD).

247 werful tool for early diagnosis of rheumatic heart disease (RHD).

248 t of the genetic score on decreased coronary heart disease risk extended beyond its effect on blood p

249 ospective, population-based Kuopio Ischaemic Heart Disease Risk Factor Study, were included in the st

250 and prediabetes remain at increased coronary heart disease risk.

251 All circulatory-disease and ischaemic-heart-disease risk reduces with increasing time since ex

252 ABC-CHD (Age, Biomarkers, Clinical-Coronary Heart Disease) risk score (p for interaction = 0.0007).

253 in small series of patients with structural heart disease (SHD) and recurrent ventricular tachyarrhy

254 pulation among subjects with stable ischemic heart disease (SIHD) and acute coronary syndromes (ACS)

255 ominant disorder characterized by congenital heart disease, skeletal abnormalities, and failure to th

256 sociation of obesity with diabetes, coronary heart disease, specific cancers, and other conditions, t

257 The hazard ratios for incident coronary heart disease, stroke, and CVD associated with a 1-SD de

258 ecific dietary factors with mortality due to heart disease, stroke, and type 2 diabetes (cardiometabo

259 Obesity-related conditions including heart disease, stroke, and type 2 diabetes are leading c

260 ted absolute and percentage mortality due to heart disease, stroke, and type 2 diabetes in 2012.

261 d Measures: Incident CVD, including coronary heart disease, stroke, or death from cardiovascular caus

262 r various causes of death, including cancer, heart disease, stroke, respiratory disease, and infectio

263 n her offspring's risks of obesity, coronary heart disease, stroke, type 2 diabetes, and asthma.

264 ODS AND We enrolled 335 consecutive valvular heart disease subjects who underwent echocardiography at

265 hed risk factors in several highly dangerous heart diseases, such as ventricular fibrillation and con

266 ever, do not have access to adult congenital heart disease tertiary centers with experienced reproduc

267 ts with congestive heart failure or ischemic heart disease than in those without (P = 0.021 for inter

268 rts, carriers of CHIP had a risk of coronary heart disease that was 1.9 times as great as in noncarri

269 ystolic heart failure not caused by ischemic heart disease, the association between the ICD and survi

270 o effect modification by history of coronary heart disease, the false-positive rates of association t

271 Early infant deaths from critical congenital heart disease through December 31, 2013, decreased by 33

272 tions in developed countries, from rheumatic heart disease to a degenerative calcific pathogenesis.

273 array of pathologic conditions ranging from heart disease to diabetes and even to cancer.

274 tatus compared with patients with left-sided heart disease-TR with sinus rhythm.

275 modeling differ between AF-TR and left-sided heart disease-TR.

276 those aged 18 years or older with ischaemic heart disease undergoing planned stent implantation in d

277 usion In older adults without prior coronary heart disease, underlying greater LV diffuse fibrosis is

278 centers with a specialized adult congenital heart disease unit.

279 s and associated such presence with coronary heart disease using samples from four case-control studi

280 e such as congestive heart failure, ischemic heart disease, valvular heart disease, pulmonary hyperte

281 al fibrillation (AF) and coexisting valvular heart disease (VHD) is of substantial interest.

282 In 2011, critical congenital heart disease was added to the US Recommended Uniform Sc

283 Coronary heart disease was an independent predictor of major adve

284 Increased severity of coronary heart disease was associated with lipoprotein(a) concent

285 e of sudden cardiac arrest due to structural heart disease was uncommon during participation in compe

286 3 has been shown to protect against coronary heart disease; we identified APOC3 homozygous pLoF carri

287 eral neuropathy, diabetic foot, and ischemic heart disease were 21.9%, 17.6%, 28.0%, 6.2%, and 23.9%,

288 e level, black race, older age, and ischemic heart disease were associated with troponin elevation.

289 mortality due to and prevalence of rheumatic heart disease were observed in Oceania, South Asia, and

290 individuals with COPD, and 39 with ischaemic heart disease were recruited.

291 ETP inhibitor anacetrapib decreased coronary heart disease when added to statin therapy.

292 s demonstrated for (a) evaluating congenital heart disease, where the impact of bulk motion is reduce

293 Patients with complex congenital heart disease, who may have undergone previous palliativ

294 role of Fam20C-dependent phosphorylation in heart disease will open new avenues for potential therap

295 y, most female children born with congenital heart disease will reach childbearing age.

296 liver lymphatic embolization and congenital heart disease with elevated central venous pressure comp

297 Despite the reduced incidence of coronary heart disease with intensive risk factor management, peo

298 eight was <50 kg or the patient had coronary heart disease), with dose adjustment according to the th

299 trial arrhythmia in patients with congenital heart disease, with a predominantly paroxysmal pattern.

300 mmonly attributable to coexistent congenital heart disease, with different risks depending on the spe